249 results about "Drug administration" patented technology

A modular disease management system may provide medication management for a patient. The system may include a base configured to at least partially couple to a tissue site of a patient. The system may further include a medication bladder coupled to the base and configured to maintain medication. The system may further include a medication pump coupled to the medication bladder, comprising a conduit and muscle wire-actuated plungers, wherein the medication pump is configured to cause the medication to flow from the medication bladder through the conduit. The system may further include a cannula insertion device coupled to the medication pump via the conduit, wherein the cannula insertion device comprises a cannula, a spring, and a triggering component, wherein the cannula insertion device is configured to insert the cannula into the tissue site of the patient by actuation of the spring released by the triggering component.

The invention discloses an intelligent decision-making method for a cerebral ischemia drug administration time window, and relates to the technical field of intelligent decision-making. The method comprises the following steps: S1, acquiring parameters, and setting a cerebral ischemia drug configuration scheme; s2, extracting a medicine characteristic parameter set and a medicine taking influence parameter set; s3, calculating a drug combination risk parameter set; s4, performing hierarchical classification processing on the drug combination risk parameter set, and performing drug correlation analysis; s5, performing weighted fusion on a correlation analysis result in combination with a drug influence attenuation rule, generating a drug administration time window evaluation parameter, and adding a label; and S6, according to the parameters, the labels and the configuration scheme, generating a cerebral ischemia drug administration time window intelligent decision scheme, and performing storage and backup. According to the method, by combining directional extraction of the drug characteristic parameter set and the drug taking influence parameter set with Pearson correlation algorithm screening, decision errors caused by data deviation are avoided.

The invention discloses a non-invasive skin drug delivery control method and system based on big data analysis, and the method comprises the steps: collecting multi-dimensional data, such as skin thickness, metabolic capability, allergic constitution, electrical impedance value, skin temperature and humidity, through a physiological parameter sensor array, and carrying out the classification and recognition of individual physiological features through a clustering algorithm. When individual parameters exceed a preset penetration threshold value, a real-time monitoring module is automatically activated, the drug administration intensity adjustment direction is judged by analyzing electrical impedance value fluctuation characteristics, a penetration depth prediction model is constructed by fusing skin temperature data, and deviation feedback optimization of a prediction value and an actual monitoring value is achieved. Allergic physical characteristics are further extracted and combined with metabolic capacity data to construct a dynamic regulation and control sequence, personalized administration intensity parameters are generated to drive an actuator to adjust equipment output, continuous and accurate permeation rate control is achieved through loop iterative optimization, the contradiction between individual differential administration requirements and equipment standardized output is effectively solved, and the method is suitable for large-scale popularization and application. The safety and the effectiveness of noninvasive administration are obviously improved.

The present invention relates to a novel polymorph of (1R,2R,3aS,3bR,10aS,10bR,11S,12aS)-5,10b-difluoro-1-(((fluoromethyl)thio)carbonyl)-11-hydroxyl-2,10a,12a-trimethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecylhydrocyclapenta[5,6]napththo[1,2-F]indazole-1-furan-2-carboxylate ester as shown in formula (I), a preparation method therefor, and a use thereof. The crystal form of the present invention has characteristics such as a significant pharmaceutical effect, good stability, high yield, and high purity, and is beneficial for the selection and design of a drug administration route and the determination of a drug preparation process parameter, thereby improving drug production quality.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.

This invention discloses an iontophoresis gel scleral contact lens and its preparation method, comprising a contact lens frame, a polymer porous microsphere drug-carrying layer loaded with nano-sustained-release drugs, an electrode layer, and a flexible material covering the electrode layer on the contact lens frame, and a gel layer covering the outer side of the contact lens frame. This iontophoresis gel scleral contact lens has a simple structure, facilitates convenient and rapid drug delivery, and provides sustained-release efficacy. It allows patients to self-administer the drug, directly delivering it to the intraocular lesion site, avoiding adverse reactions in other tissues or the whole body, and has a sustained-release function to reduce the frequency of drug administration.

This medication management device comprises an acquisition unit, a storage unit, and a control unit. The acquisition unit acquires drug administration information including an administration amount and an administration time of a drug for a patient. The storage unit stores past drug administration information of the patient as drug administration history information. The control unit estimates an in-vivo drug concentration of the patient on the basis of the drug administration history information, and executes, on the basis of the estimated in-vivo drug concentration of the patient, a process determined from a plurality of different processes.

The application discloses a deformable red blood cell preparation targeting liver and a preparation method and application thereof. The deformable red blood cell preparation comprises red blood cells and a deformable agent combined on the red blood cell membrane. The deformable agent comprises a CpG oligonucleotide. The deformable red blood cell preparation of the application highly targets liver by using the natural immune homing property of deformable red blood cells, and can reduce the toxic side effects of drugs and increase the safety of drug administration. Meanwhile, the deformable red blood cell preparation of the application has a simple preparation process, and raw materials are economical and easy to obtain, and the preparation process does not need to depend on complex equipment and is easy to industrialize.

This application belongs to the field of biomedicine, specifically relating to a method for preparing an antitumor composition for pets, aiming to solve the technical problems of low bioavailability, poor stability, and poor drug administration compliance of poorly soluble active ingredients in antitumor drugs for pets. The method includes: a raw material pretreatment step, in which curcumin, resveratrol, quercetin, green tea polyphenols, and astragalus polysaccharides are pulverized and sieved separately; an organic phase preparation step, in which egg yolk lecithin and solid lipids are dissolved in an ethanol-acetone mixed solvent, and curcumin and resveratrol are added and dissolved by stirring in a water bath; an aqueous phase preparation step, in which poloxamer F68 is dissolved in purified water and dissolved in a water bath; a high-pressure homogenization step, in which a nanoemulsion containing a solid lipid core is prepared; a moderately polar component encapsulation step, in which quercetin and green tea polyphenols are ultrasonically dispersed and then added dropwise to the nanoemulsion; a freeze-drying step, in which a nano-lyophilized powder is obtained; and an outer hydrophilic component coating step, in which astragalus polysaccharides are sprayed or adsorbed onto the surface of the freeze-dried powder. The composition obtained by this method is a core-shell multilayer nanoparticle with a core consisting of curcumin and resveratrol encapsulated by solid lipids, a middle shell adsorbing quercetin and green tea polyphenols, and an outer shell coated with astragalus polysaccharides. This application utilizes the above-mentioned layered encapsulation technology to achieve stable co-encapsulation of multiple antitumor active ingredients, improve the bioavailability of poorly soluble components, optimize drug stability, and enhance antitumor effects through multi-target synergistic effects. Simultaneously, it endows the composition with immunomodulatory functions and sustained-release properties. The composition can be formulated into a nano-lyophilized powder form, making it easy to add to pet food or formulate into a paste for administration, improving pet drug compliance. Figure 2 is a schematic diagram of the three-layer core-shell nanoparticle structure of the composition of this invention.

The invention relates to the technical field of medical instruments, in particular to a multi-channel oropharyngeal ventilation device for the anesthesiology department, the multi-channel oropharyngeal ventilation device for the anesthesiology department comprises a ventilation pipe, a functional pipe and a mounting plate, two through holes are symmetrically formed in the side face of the mounting plate, and the ventilation pipe and the functional pipe are arranged in parallel and movably connected to the inner walls of the through holes of the mounting plate respectively; the device further comprises a guide plate fixedly connected to the middle of the mounting plate, occlusion blocks are symmetrically connected to the two sides of the guide plate in a sliding mode, the occlusion blocks are used for being occluded and limited between the upper teeth and the lower teeth of a patient, and the ends, facing ventilation, of the occlusion blocks are arc-shaped end faces. Through the vent pipe and the functional pipe which are arranged in parallel, ventilation support and clinical drainage, dosing and other operations in an anesthesia state are achieved respectively, repeated intubation is avoided, the locking assembly is matched to automatically lock the vent pipe and the functional pipe at the target depth after the device is in place, a catheter is effectively prevented from sliding or dislocation in an operation, and the operation efficiency is improved. And the accuracy and the safety of medical operation are ensured.

The present application relates to the technical field of health care products, in particular to a pelvic floor muscle repairing composition containing supermolecular tightening Dropsordry and a preparation method thereof, which comprises the following components in mass fraction: 10-14 parts of protein composition, 20-24 parts of chitosan modified Dropsordry, 5-7 parts of freeze-dried powder of Lactobacillus bulgaricus, 10-12 parts of hyaluronic acid, 6-8 parts of glycine and 15-17 parts of proline; each part of the protein composition comprises 20-30 parts of myosin, 30-34 parts of actin, 5-10 parts of hydrolyzed collagen and 240-280 parts of deionized water. The pelvic floor muscle repairing composition can reduce drug toxicity, reduce the amount of drug administration, continuously supplement the required elements of the body during treatment, and quickly relieve the constipation problem caused by the functional damage of the pelvic floor muscle.

The present invention belongs to the technical field of medical devices, and in particular, relates to a vaginal function exerciser, including: an inserting end, an irrigating pipeline being arranged at a front end of the inserting end, and an expansion unit being arranged at a middle part of the inserting end; and a host, a first port of the host communicating with the expansion unit through a second hose, a second port of the host communicating with the irrigating pipeline through a first hose. A camera is arranged at the front end of the inserting end, and the camera is electrically connected to a third port of the host through a power supply and signal line. The vaginal function exerciser achieves multiple functions of vaginal exercise and irrigation, so that a patient can perform vaginal irrigation, drug administration and dilation under the guidance of a doctor.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The present application relates to providing a doxorubicin-loaded anti-tumor hemostatic microsphere constructed by a simple, safe and low-cost method and its preparation and application, the doxorubicin-loaded anti-tumor hemostatic microsphere comprises alginate, hemostatic component A, doxorubicin or doxorubicin liposome, crosslinking agent, the hemostatic component A is selected from one or more of carboxymethyl chitosan, hyaluronic acid, collagen, silk fibroin, solve the practical pain point problems such as easy bleeding in tumor resection surgery, large toxicity of chemotherapeutic drugs, large drug dose, frequent drug administration, etc., realize rapid hemostasis in operation, postoperative precise targeted drug delivery, reduce toxic side effects, long-acting drug sustained release, at the same time, all components of the system are safe and reliable, and have good biocompatibility.

The invention provides a memantine derivative or a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of the memantine derivative, and application of the memantine derivative in preparation of drugs for preventing and / or treating central nervous diseases, especially Alzheimer's disease, Parkinson's disease or other neurodegenerative diseases. The compound disclosed by the invention is small in water solubility, can be well prepared into a suspension preparation, has a relatively low dissolution speed in a living body, can achieve the effect of lasting the drug effect for several weeks after single administration, reduces the medication frequency of a patient, improves the compliance of the patient, also ensures the curative effect, and has a relatively good application prospect.

The invention relates to a tailorable anti-fungal multi-point penetrating press-fit sewing dressing and preparation and application thereof.The method comprises the following steps that a high polymer material solution and an anti-fungal medicine solution are mixed, liquid-phase matter is subjected to defoaming treatment, spinning is conducted, curing is conducted through a fixing solution, and the tailorable anti-fungal multi-point penetrating press-fit sewing dressing is obtained; performing rinsing, drying, opening, needling, freeze-drying and vacuum drying on the obtained condensate, and then compounding the condensate with a gelatin layer and a surface layer to obtain the tailorable antifungal multi-point penetrating press-fit sewing dressing. Compared with the prior art, the preparation method has the advantages that an antifungal drug is introduced and compounded with a high polymer material, the compound is prepared into the drug-containing fiber, and then the drug-containing fiber layer and other material layers are prepared into a final product through a modern textile technology. The product can realize long-acting sterilization and bacteriostasis, and solves the problems of difficult administration, poor curative effect, repeated disease course, patient compliance and the like of body surface fungal infection at present.

Cardiopulmonary resuscitation demands rapid and precise responses, particularly in hospital emergency departments. The "Automated Resuscitation Trolley Alert and Drug Dosage System" is designed as an add-on compatible with various resuscitation trolleys. The system features a powerful central processing unit, a liquid-resistant capacitive touchscreen, an audio-visual alert system with high-power LEDs, and communication modules for hospital network integration. It uses artificial intelligence and machine learning algorithms to calculate drug dosages based on patient information and monitoring data. The audio-visual alert system reduces medical team response times in emergencies. Connectivity to hospital information systems enables quick access to patient data and automatic logging of actions. By enhancing precision and speed in drug administration, minimizing human errors, and improving team coordination, this invention significantly improves the quality of emergency services and the success rate of resuscitation procedures.

This application discloses a sustained-release formula and medicated pillow for the prevention and treatment of allergic rhinitis, including a pillow base with two symmetrically arranged sustained-release mechanisms and a drive mechanism in the bottom mounting compartment. The sustained-release mechanism consists of multiple sustained-release components, each containing a sustained-release tube and a drug storage tube, connected by a U-shaped connecting pipe and a one-way valve; the drug storage tube is inserted into a pierced tube with a filter screen, which balances air pressure and prevents contamination. The drive mechanism drives a sliding valve to reciprocate via a worm gear system, achieving quantitative drug extraction and precise sustained-release; the atomization design of the sustained-release port improves drug absorption efficiency, and the guide holes in the mounting compartment and the ventilation grooves on the pillow surface form a uniform diffusion channel. This solution solves the problems of cumbersome drug replacement, uncontrollable volatilization, and easy deterioration associated with traditional medicated pillows, offering advantages such as precise controlled release, convenient maintenance, and multiple safety protections. It allows for individualized drug administration based on drug characteristics and patient rhythms, significantly improving the effectiveness of sleep aid therapy and the user experience.

The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of Nos1 (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.

The invention discloses a vagina contracting rod for recovery of pelvic muscle relaxation in the gynecology department, and belongs to the technical field of medical instruments, the vagina contracting rod comprises a rod body and a liquid injection head mounted at one end of the rod body, a plurality of groups of groove bodies are formed in the rod body and are linearly distributed at equal intervals, and a medicine storage mechanism and an acupuncture mechanism are arranged in each groove body; the medicine storage mechanism comprises a medicine storage bag and a connecting groove, the medicine storage bag is arranged in the groove body, the connecting groove is formed in the side, close to the liquid injection head, of the groove body, the medicine storage bag is located between the connecting groove and the needling mechanism, and a needling head of the needling mechanism is arranged opposite to the connecting groove. Through the linkage design of the locking mechanism and the supporting mechanism, sequential release of the multiple medicine storage mechanisms is achieved, the requirement for repeated and continuous medicine administration in the treatment process is met, frequent medicine replacement or repeated injection is avoided, the medicine administration process can be automatically completed through unlocking operation of the locking mechanism, external auxiliary equipment is not needed, and the operation is convenient. The patient can conveniently use the device at home.

The invention relates to a multifunctional capsule robot integrating dual-channel biopsy, drug administration and anchoring functions, which comprises a shell, a capsule, a capsule, a capsule and an anchoring device, wherein a bracket is arranged in the shell; the three-degree-of-freedom magnetic driving assembly is arranged on the bracket, and the three-degree-of-freedom magnetic driving assembly is arranged on the bracket; the tool switching mechanism is used for switching different tool cabins, and the tool switching mechanism is installed on the support; the four tool cabins respectively have the functions of 30G biopsy, 25G biopsy, drug A administration and drug B administration, are used for supporting the realization of double-channel biopsy and double-channel administration, and are mounted on a four-phase tool wheel disc of the tool switching mechanism; and the deformation anchoring mechanism is used for being fixed near a focus, and the deformation anchoring mechanism is connected with the support. The device is used for diagnosis and treatment of human body lumen organs such as digestive tracts, is suitable for multi-part tissue sampling, multi-drug precise administration and stable anchoring operation under the non-invasive or minimally invasive condition, realizes function cooperation through the four-phase tool wheel disc, and flexibly switches the working state between two-channel biopsy and drug administration; and an integrated solution is provided for diagnosis and treatment of intracavity diseases.

Use of cyclodextrin and its derivatives as protective agent in preparation of TACI-Fc fusion protein liquid drug preparation. The use of cyclodextrin as a protective agent can improve the long-term stability of TACI-Fc fusion protein, maintain good biological activity, improve drug production efficiency and greatly improve the convenience of drug administration.

This utility model discloses an integrated multifunctional intubation device with flushing, drainage, and drug administration functions. The device includes an intubation tube, a three-way drug administration flushing and drainage device, a connecting tube, and an anti-backflow negative pressure drainage ball. The inner surface of the intubation tube has supporting teeth to prevent compression closure. One end is a connecting section, and the working section's tail end is fish-mouth shaped with staggered flushing holes on its smooth surface. The outer circumference of the intubation tube has an "I"-shaped fixing ring. The three-way valve is connected to the anti-backflow negative pressure drainage ball through the connecting tube, allowing liquid in the intubation tube to flow into the drainage ball, preventing backflow and allowing liquid to flow out through the drain hole. The connections between the connecting tube, the intubation tube, and the three-way valve are all threaded and tightened. This device integrates multiple functions, has a reasonable structural design, and can effectively realize flushing, drainage, and drug administration operations, while also preventing blockage of the intubation tube due to compression and dislodgement due to external force.

A drug administration management method according to one embodiment disclosed herein may comprise the steps of: receiving identification information of a first drug from a pharmacist terminal; transmitting permission information corresponding to the identification information of the first drug to the pharmacist terminal; receiving customized medication guidance, in which the permission information is personalized according to patient profile information of a patient, from the pharmacist terminal, and storing the customized medication guidance in a patient information database; receiving identification information of a drug from a patient terminal and searching for the identification information of the drug in an internal database; and generating a customized administration schedule for the patient according to administration schedule information of the first drug included in the customized medication guidance if the searched identification information of the drug is the identification information of the first drug.

The application provides a long-acting external use efinaconazole composition, a preparation method and application, and belongs to the technical field of pharmaceutical compositions.The long-acting external use efinaconazole composition comprises the following components in percentage by weight: efinaconazole 0.5-3%, a film forming agent 3-7%, a gel agent 2-3%, a plasticizer 3-7%, a cosolvent 0.78-1.56% and a solvent in a residual amount.The application forms a eutectic mixture of efinaconazole and lactic acid, improves the solubility and permeability of the active ingredient, dissolves in the solvent of an ethanol system, and adds the film forming agent and the plasticizer, so that a drug depot is formed on the surface of the skin through the film forming principle, the drug is released slowly, the clinical compliance is improved, the frequency of drug administration is reduced, the bioavailability of the drug in the stratum corneum is increased, the effectiveness and safety of the drug can be improved, the basic theory of pharmacoeconomics is met, and the clinical value of the product is improved.

The present application relates to devices and methods for determining a drug administration regimen for a subject. Determining an administration regimen for a subject comprises calculating an amount of drug that needs to be administered to the subject per a base period, and determining and evaluating a combination of at least two dosage forms that can be used to administer the amount of drug against at least two different criteria. The methods of the present application can be used to select an administration regimen for a drug that is available in a plurality of dosage forms, especially a drug that is administered on a long-term daily basis, such as in the daily prophylaxis of hemophilia.

The invention discloses a lipophilic modified nucleic acid medicine composition and application thereof, the lipophilic modification is saturated or unsaturated C4-C30 alkyl, the composition comprises an absorption enhancer, and the method is that the lipophilic modified nucleic acid medicine is delivered to the brain through the nasal mucosa. Nucleic acid drugs are transmitted into the olfactory bulb region through a neural pathway, namely, cross-olfactory mucosa, bypass BBB and directly enter the brain, the drug concentration content of the olfactory bulb is far higher than that of other tissues of the brain, and the tissues except the olfactory bulb are uniformly distributed, so that the olfactory bulb can be used as a drug reservoir and gradually and slowly spread to the other tissues of the brain; the long-time drug effect can be maintained by one-time drug administration, so that the drug administration frequency can be reduced. Compared with intrathecal injection, by adopting the composition disclosed by the invention for nasal administration and using 1 / 2 of intrathecal administration dosage, the same intrathecal steady-state distribution as intrathecal distribution can be achieved, so that the method disclosed by the invention is safer, noninvasive and efficient.

This invention discloses a nanodecoy receptor that blocks the IL-17 signaling pathway, including IL-17RA-CMVs carrying a fusion sequence of PDGFR-TMD and IL-17RA. This invention also provides a method for preparing the aforementioned nanodecoy receptor that blocks the IL-17 signaling pathway, comprising the following steps: S1. Using genetic engineering, IL-17RA and PDGFR-TMD are fused and designed, and a lentivirus carrying the IL-17RA and PDGFR-TMD fusion sequence is coated onto mammalian cells. A cell line stably expressing the IL-17RA and PDGFR-TMD fusion sequence is established in mammalian cells through lentivirus transfection; S2. The cell line from step S1 is taken, and cell membrane vesicles are prepared by ultrasonic disruption and permeabilization extrusion until the fusion sequence of IL-17RA carrying PDGFR-TMD is displayed at high density and correctly oriented on the outer surface of the cell membrane vesicles, forming IL-17RA-CMVs. The nano-decoy receptor of the present invention can efficiently and broadly block the interaction between IL-17 and IL-17RA, avoid such systemic side effects, and achieve treatment only through local minimally invasive delivery, thus solving the side effects problem caused by existing systemic drug administration.

This utility model relates to a simple experimental mouse fixation and tail vein injection device, including a fixation platform, a transparent isolation cover, and a tail fixation component. The transparent isolation cover is used to cover the experimental mouse on the fixation platform. An isolation cover notch is formed at the edge of the open end of the transparent isolation cover, through which the tail of the experimental mouse protrudes. The tail fixation component is used to fix the protruding tail of the experimental mouse on the fixation platform. This utility model combines experimental mouse fixation, tail fixation, and visual monitoring, achieving a dual improvement in drug administration accuracy and simplified experimental operation. It can be operated by a single person and is suitable for precise drug delivery and real-time image monitoring in small animal experiments, possessing high practical value and promising prospects for widespread application.